myEDIT-B: towards precision psychiatry through faster differential diagnosis

Earlier identification of bipolar disorder is a major public health challenge. On average, eight years elapse between the first symptoms and the implementation of appropriate treatment (McIntyre et al., 2020). This delay leads to significant clinical and social consequences, including worsened symptoms, relapses, excess mortality and impaired quality of life. This is why Clariane is working with Alcediag to roll out the myEDIT-B test as part of a pilot project in France and Spain, in partnership with SYNLAB International. This innovative blood test, based on RNA editing and artificial intelligence, could help clinicians distinguish unipolar depression from bipolar disorder – a central diagnostic challenge in psychiatry.

An innovation to refine and accelerate diagnosis

myEDIT-B does not replace clinical evaluation, but complements it by providing objective biological data that helps psychiatrists better guide their therapeutic decisions. The test has an accuracy of more than 80%, promoting a faster and more reliable diagnosis, allowing tailored care and guiding treatment decisions.

Available on prescription, it is intended for adult patients receiving treatment for a moderate to severe depressive episode and helps psychiatrists refine the differential diagnosis between depression and bipolar disorder and personalise the care they provide.

A European pilot study in real-world conditions

The real-world acceptability study was conducted with 63 adult patients receiving treatment for a moderate to severe major depressive episode within several of the group’s facilities: Inicea in France and Ita Salud Mental and Hospital Clínic de Barcelona in Spain. Blood samples were taken in SYNLAB laboratories.

The first results from the study were presented at the European Congress of Neuropsychopharmacology (ECNP) in Amsterdam in October 2025. They highlight psychiatrists’ strong backing for this innovative solution and confirm its relevance as a diagnostic assistance tool.

Very positive results in the field

The psychiatrists who took part in the study emphasised the test’s ease of use and its practical value in everyday practice:

• 83% report that myEDIT-B helped them guide or redirect patients’ treatment;
• 100% believe that it has strengthened the therapeutic alliance with their patients;
• 67% consider that it has helped reduce the time to diagnosis;
• 92% indicate that it made communicating the diagnosis easier;
• 92% say it confirmed or disproved the initial diagnosis.

The results confirm that myEDIT-B improves diagnostic confidence, supports clinical decision making and strengthens the relationship between the psychiatrist and the patient – three essential components of more accurate, more human psychiatry.

Tangible benefits for patients and teams

For psychiatrists, it offers an objective, reliable decision support tool. For patients, it represents a concrete step forward: a more accurate diagnosis, more appropriate treatment and better understanding of their disorder.

Next steps: measuring the impact on care pathways

Clariane is continuing to assess the impact of myEDIT-B on how care is organised and coordinated within its facilities, in particular by monitoring the pathways of patients who have benefited from the tool.  The aim is to optimise myEDIT-B’s integration into clinical protocols and maximise benefits for patients and care teams. This is an important step for measuring the usability and acceptability of precision medicine within our facilities.